Efficacy of Delafloxacin Versus Moxifloxacin Against Bacterial Respiratory Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results From the Delafloxacin Phase 3 CABP Trial

Antimicrobial Agents and Chemotherapy - United States

doi 10.1128/aac.01949-19